Platform Extension
Pulmonary Embolism (PE)
Key Facts
About Retriever Medical
Retriever Medical is a pre-revenue, clinical-stage medical device company targeting the venous thrombectomy market with its ClotHound™ system. The device is engineered to mechanically engage and remove acute, sub-acute, and chronic wall-adherent thrombus while providing distal embolic protection, a key differentiator. The company is advancing the system through preclinical validation with a regulatory pathway targeting 510(k) clearance for DVT, and the platform has potential future applications in pulmonary embolism and complex venous thrombosis. Founded in 2016, the company is headquartered in San Jose, California.
View full company profileAbout Retriever Medical
Retriever Medical is a pre-revenue, clinical-stage medical device company targeting the venous thrombectomy market with its ClotHound™ system. The device is engineered to mechanically engage and remove acute, sub-acute, and chronic wall-adherent thrombus while providing distal embolic protection, a key differentiator. The company is advancing the system through preclinical validation with a regulatory pathway targeting 510(k) clearance for DVT, and the platform has potential future applications in pulmonary embolism and complex venous thrombosis. Founded in 2016, the company is headquartered in San Jose, California.
View full company profileAbout ni2o
ni2o is a private, pre-revenue biotech startup founded in 2018, aiming to revolutionize the treatment of neurodegenerative diseases through an integrated AI and neuromodulation platform. The company's three-pillar approach includes an AI software for early detection (4cyte AI), a wearable EEG headcap for monitoring (tKIWI), and a micro-implant for therapy (KIWI Micro-Implant). While ambitious and technologically novel, the company is in a pre-clinical or early development stage, facing significant technical, regulatory, and commercial hurdles inherent to the neurotech space. Its success hinges on validating its platform and translating its vision into approved medical devices and therapies.
View full company profileTherapeutic Areas
Other Pulmonary Embolism (PE) Drugs
| Drug | Company | Phase |
|---|---|---|
| Katana Thrombectomy System | Akura Medical | Pivotal Trial |
| FlowTriever System | Inari Medical | Commercial / PMA Supplement |